Cannabix Technologies Announces Detection of Cocaine and Benzoylecgonine in Human Breath

Vancouver, British Columbia, July 6, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing technologies for workplace safety and law enforcement, announces detection of cocaine and its primary metabolite, benzoylecgonine, in human breath samples tested with the Marijuana Breath Test ("MBT"). Human breath samples were collected using the Cannabix Breath Collection Unit (“BCU”) and were analyzed by Omega Laboratories Inc. ("Omega") utilizing liquid chromatography-mass spectrometry ("LC-MS").

 Cocaine Detection in Breath Represents a Significant New Opportunity

Benzoylecgonine, the principal metabolite of cocaine, is routinely used by forensic and clinical laboratories to confirm cocaine use. The successful identification of both cocaine and benzoylecgonine demonstrates that the Cannabix MBT (consisting of the Cannabix BCU, disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega Laboratories) can capture these trace-level drug compounds from exhaled breath.

The Company believes these findings demonstrate application of the Cannabix MBT and the associated legally defensible chain of custody and analytical process beyond THC detection and allows for broader multi-drug breath testing applications for workplace safety, transportation, industrial, rehabilitation, and law enforcement markets.

Rav Mlait, CEO of Cannabix Technologies, stated, "Detecting cocaine and benzoylecgonine in human breath is significant because these compounds are exceptionally difficult to measure in breath. The concentrations are extremely low, making both breath collection and laboratory confirmation technically demanding."

Cocaine use is illegal and presents a significant safety concern in any industry.